Blood Pressure Effects of Intravenous Apomorphine in Conscious Deoxycorticosterone-Acetate Salt-Hypertensive Rats

Journal of Cardiovascular Pharmacology

Volumn 42, Issue 6, 2003, Pages 772-781

  Toscano, Carla Fabiana ^a   Lahlou, Saad ^a,b  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b DEPARTAMENTO DE MICOLOGIA   (Brazil)

Author keywords

Apomorphine; Arginine vasopressin; Autonomic nervous system; Blood pressure; DOCA salt hypertension; Dopamine D2 receptors; Spinal

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; APOMORPHINE; ARGIPRESSIN; DEOXYCORTICOSTERONE ACETATE; DOMPERIDONE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HEXAMETHONIUM; METOCLOPRAMIDE; NORADRENALIN; PRAZOSIN; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; DEPRESSOR RESPONSE; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESPONSE; EXPERIMENTAL MODEL; EXPERIMENTAL RAT; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PERIPHERAL CIRCULATION; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; SPINAL CORD; SYMPATHETIC TONE; VASOPRESSIN RELEASE;

ANIMALS; APOMORPHINE; BEHAVIOR, ANIMAL; BLOOD PRESSURE; DESOXYCORTICOSTERONE; DOMPERIDONE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GANGLIONIC BLOCKERS; HEXAMETHONIUM; HYPERTENSION; INJECTIONS, INTRAVENOUS; MALE; RATS; RATS, WISTAR;

EID: 0345017112     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200312000-00012     Document Type: Article

References (38)

1. Ondo W, Hunter C, Almaguer M, et al. Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease. Clin Neuropharmacol. 1999;22:1-4.
2. Manson AJ, Turner K, Lees AJ. APO monotherapy in the treatment of refractory motor complications in Parkinson's disease: Long-term follow-up study of 64 patients. Mov Disord. 2002;17:1235-1241.
3. Heaton JP, Morales A, Adams MA. Recovery of erectile function by the oral administration of apomorphine. Urology. 1995;45:200-206.
4. Padma-Nathan H. A new era in the treatment of erectile dysfunction. Am J Cardiol. 1999;84:18N-23N.
5. Pollak P, Mallaret M, Gaio JM. Blood pressure effects of apomorphine and domperidone in Parkinsonism. Adv Neurol. 1987;45:263-266.
6. Rascol O, Montastruc JL. Cardiovascular effects of apomorphine in humans: evidence for peripheral mechanisms. Clin. Neuropharmacology. 1986;9:566-569.
7. Finch L, Haeusler G. The cardiovascular effects of apomorphine in the anaesthetized rat. Eur J Pharmacol. 1973;24:264-270.
8. Ramirez AJ, Enero MA. Blood pressure and heart rate responses to apomorphine in urethane anesthetized rats. Acta Physiol Pharmacol Ther Latinoamer. 1980;30:199-203.
9. Mugabo P, Buylaert W, Bogaert M. Cardiovascular effects of apomorphine in the rat. Arch Int Pharmacodyn Ther. 1983;262:324-325.
10. Chueh FY, Hsieh MT, Chen CF, et al. DL-Tetrahydropalmatine-produced hypotension and bradycardia in rats through inhibition of central nervous dopaminergic mechanisms. Pharmacology. 1995;51:237-244.
11. van den Buuse M. Central effects of quinpirole on blood pressure of spontaneously hypertensive rats. J Pharmacol Exp Ther. 1992;262:303-311.
12. Lahlou S, Petitjean P, Pellissier G, et al. Rostrocaudal localization of cardiovascular responses induced by intrathecal administration of apomorphine in conscious, freely moving rats. J Cardiovasc Pharmacol. 1990;16:331-337.
13. Lahlou S. Cardiovascular responses to intrathecal dopamine receptor agonists in conscious DOCA-salt hypertensive rats. Fundam Clin Pharmacol. 1999;13:624-634.
14. Pellissier G, Demenge P. Hypotensive and bradycardic effects elicited by spinal dopamine receptor stimulation: effects of D1 and D2 receptor agonists and antagonists. J Cardiovasc Pharmacol. 1991;18:548-555.
15. Lahlou S. Mechanisms underlying the cardiovascular responses to spinal dopamine receptor stimulation by apomorphine in anesthetized rats. Neurosci Lett. 2003;335:187-191.
16. Takano Y, Martin JE, Leeman SE, et al. Substance P immunoreactivity released from rat spinal cord after kainic acid excitation of the ventral medulla oblongata: a correlation with increases in blood pressure. Brain Res. 1984;291:168-177.
17. Montastruc JL, Llau ME, Senard JM, et al. A study of tolerance to apomorphine. Br J Pharmacol. 1996;117:781-786.
18. Roquebert J, Moran A, Sauvage MF, et al. Effects of quinpirole on autonomic nervous control of heart rate in rats. Fundam Clin Pharmacol. 1992;6:67-73.
19. 2 receptor agonist, in the anesthetized rat. J Pharmacol Exp Ther. 1986a;239:426-432.
20. 2 dopamine receptor agonist quinpirole in rats. Fundam Clin Pharmacol. 1987;1:179-200.
21. Petitjean P, Mouchet P, Pellissier G, et al. Cardiovascular effects in the rat of intrathecal injections of apomorphine at the thoracic spinal cord level. Eur J Pharmacol. 1984;105:355-359.
22. Lahlou S, Demenge P. Contribution of spinal dopamine receptors to the hypotensive action of bromocriptine in rats. J Cardiovasc Pharmacol. 1991;18:317-325.
23. 2 receptor agonist, in the conscious rat. J Pharmacol Exp Ther. 1986b;236:735-742.
24. Creese I, Iversen SD. Blockade of amphetamine-induced motor stimulation and stereotypy in the adult rat following neonatal treatment with 6-OHDA. Brain Res. 1973;55:396-402.
25. Lahlou S, Pinto Duarte G. Hypotensive action of bromocriptine in the DOCA-salt hypertensive rat: contribution of spinal dopamine receptors. Fundam Clin Pharmacol. 1998;12:599-606.
26. Nagahama S, Chen YF, Oparil S. Enhanced depressor effect of bromocriptine in the DOCA/NaCl hypertensive rat. Am J Physiol. 1985;18:H64-H70.
27. Bredberg E, Paalzow LK. Altered pharmacokinetics and dynamics of apomorphine in the malnourished rat: modeling of the composed relationship between concentration and heart-rate response. Pharm Res. 1990;7:318-324.
28. Kopin IJ, Lake RC, Ziegler M. Plasma levels of norepinephrine. Ann Intern Med. 1978;88:671-680.
29. Moore N, Fresel J, Joannides R, et al. A comparison of the hemodynamic effects of urpidil, prazosin, and clonidine in healthy volunteers. Blood pressure Suppl. 1994;7:7-12.
30. Grassi G, Seravalle G, Stella ML, et al. Sympathoexcitatory responses to the acute blood pressure fall induced by central or peripheral antihypertensive drugs. Am J Hypertens. 2000;13:29-34.
31. Laduron PM, Leysen JE. Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. Biochem Pharmacol. 1979;28:2161-2165.
32. Langer SZ. Presynaptic regulation of the release of catecholamines. Pharmacol Rev. 1981;32:337-362.
33. Cavero I, Massingham R, Lefevre-Borg F. Peripheral dopamine receptors, potential targets for a new class of antihypertensive agents. Part II: Sites and mechanisms of action of dopamine receptor agonists. Life Sci. 1982;31:1059-1069.
34. Lahlou S, Demenge P. Increase in the hypotensive effect of bromocriptine induced by spinal transection in rats: contribution of spinal dopamine receptors. J Cardiovasc Pharmacol. 1992;19:723-731.
35. Hökfelt T, Phillipson O, Goldstein M. Evidence for a dopaminergic pathway in the rat descending from the A11 cell group to the spinal cord. Acta Physiol Scand. 1979;107:393-395.
36. Skagerberg G, Björklund A, Lindvall O, et al. Origin and termination of the diencephalo-spinal dopamine system in the rat. Brain Res Bull. 1982; 9:237-244.
37. Feuerstein C, Mouchet P, Manier M, et al. Dopaminergic relationships in the rat spinal cord. In: Sandler M, Dahlstrom A, Belmaker RH, eds. Progress in Catecholamine Research, part B: Central aspects. New York: Alan R. Liss, 1988:529-536.
38. 2 receptors in the posterior region of the nucleus tractus solitarius mediate the central pressor action of quinpirole (LY 171555). Brain Res Bull. 1990;24:97-103.